Festschrift: : Protection mechanism of pneumococcal capsular vaccines During the 1970s, a hexavalent pneumococcal polysaccharide vaccine (PPV-6) and a 13-valent (PPV-13) trial involving ~12,000 Witwatersrand gold miners showed efficacy against pneumonia caused by vaccine types (VTs). The effect of PPV-6 and PPV-13 on nasopharyngeal carriage of pneumococcal serotypes in 600 and 200 miners, respectively, was evaluated, but was not previously published. Participants were randomised to receive PPV, meningococcal Group A vaccine (MVA) or saline placebo. Nasopharyngeal swabs were collected for pneumococcal serotype detection immediately before vaccine or placebo administration, one and 25 days after, and at the time of leaving the mine. Because PPVs failed to protect against serotype 3 carriage, analysis was confined to other VTs. PPV-6 caused a 70% reduction in percentage of VT carriage in PPV-6 recipients ( NVTs [p<0.002]). In the PPV-13 study, there were six VTs (18.2%) in PPV-13 recipients and 10 VTs (35.7%) in the MVA group, resulting in a non-significant (p=0.15) 49% reduction in carriage. A 65% reduction in carriage (p=0.0054) was demonstrated when 51% carriage (18 VTs) in the placebo group was compared with 18.2% VT carriage in PPV-13 vaccinees. Data are consistent with the hypothesis that the impact of PPVs on pneumonia may be mediated through protection from carriage.
Introduction
This year represents the centennial of the first human trial of pneumococcal vaccination, when Sir Almroth Wright commenced the inoculation of two doses of whole cell-killed pneumococcal vaccine in a randomised trial versus controls among newly recruited mine workers in South Africa in October 1911. 1 That vaccine, given without regard to capsular type, gave protection lasting only two months and led to further vaccination trials using a variety of killed pneumococcal vaccines of different capsular types by Sir Spencer Lister in the same community during the following five years. 2 The next landmark in clinical trials of vaccination against pneumococcal disease came only 30 years later when Macleod and colleagues, during the Second World War, developed and tested a 4-valent pneumococcal polysaccharide capsular vaccine (PPV) against pneumococcal serotypes 1, 2, 5 and 7. 3 This vaccine was highly successful in preventing pneumonia due to those types, and was followed again 30 years later in 1976 by the development of 6-and 13-valent polysaccharide pneumococcal vaccine trials led by Robert Austrian in the same mine worker communities within which the first trials were conducted in South Africa. 4 There were also trials of 6-and 12-valent vaccines led by Maurice Hilleman in the same type of workers in the gold mines. 5 These trials similarly showed efficacy against pneumonia caused by the vaccine types.
The use of polysaccharide vaccines has, however, been limited given the lack of established vaccination platforms for the immunisation of adults, but also because evidence from randomised trials that polysaccharide vaccines could prevent pneumonia in the target group of adults greater than 65 years of age has been lacking. 6 In contrast, the development in the 1990s of pneumococcal conjugate vaccines (PCV) has led to clear evidence from randomised double-blind trials of efficacy against chest X-ray-defined pneumonia in children who have received the vaccine. [7] [8] [9] [10] A feature of the conjugate pneumococcal vaccine trials has been clear evidence for protection also against pneumococcal acquisition of carriage due to vaccine types.
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While the pathogenesis of pneumococcal pneumonia is not clear, there is consensus that the portal of entry of the pneumococcus into the lungs starts with acquisition of carriage, which may be a necessary precursor to pneumococcal pneumonia. We have recently established that the density of pneumococcal carriage during pneumonia episodes in adults is much higher than that during asymptomatic carriage (Albrich et al, unpublished data) and this has led to the hypothesis, explored in this paper, that prevention of pneumococcal pneumonia by pneumococcal polysaccharide vaccine may be dependent on stopping the acquisition and proliferation of pneumococci in the nasopharynx.
Nasopharyngeal pneumococcal carriage was indeed assessed in the Austrian studies of PPV, and was recorded in the Master's dissertation of one of the authors (SWHS), but was never published. These data are presented in this paper.
Methods
The methods of the trials have been published. 4 Briefly, a 6-valent vaccine containing groups/types 1, 3, 4, 7, 8 and 12 (Eli Lilly and Company, Indianapolis, USA) and later a 13-valent formulation of groups/types 1, 2, 3, 4, 6, 7, 8, 9, 12, 14, 18, 19 and 25 made by Merck (USA) were administered in a randomised fashion (0.5 ml dose) to newly recruited miners on their day of arrival at the mines in Johannesburg, South Africa. From a table of random numbers, the miners were randomly divided into three groups and given colour-coded cards to direct them to tables marked with card-matching colours, where they received the PPV or a meningococcal serogroup A polysaccharide control vaccine (Merrell-National Laboratories) or a sterile saline injection serving as a second control. Vaccinees then received a form to keep with them during their contract at the mine which specified the vaccine and the lot number they received, so while the study was randomised, it is unclear to what extent the allocation of the study vaccine was blinded from clinicians or laboratory personnel.
For the carriage study, 200 miners per group (a total of 600 miners) for the 6-valent vaccine study and a total of 200 miners for the 13-valent vaccine study were randomly selected to participate. A cotton swab on a wire was used and two swabs were collected per person. For pneumococcal culture, the one swab was cultured on Columbia blood agar at 37°C in a 10% carbon dioxide candle jar. Pneumococci were identified according to standard laboratory methods at that time, 12 and serotyping was performed by the Quellung reaction at an independent institution in Johannesburg, namely the South African Institute for Medical Research. The second swab was placed in 3 ml of beef heart infusion broth containing 0.1 ml defibrinated rabbit blood and incubated for two to three hours, and then 0.5 ml was inoculated intraperitoneally into a white mouse. Swabs were taken on day 0 before vaccination, day 1 after vaccination, day 25, and when the miner left the mine.
Results
The number of pneumococci isolated from the miners in the 6-valent trial isolated 15 or more days post-injection are shown in Table I . The denominator of the number of individuals swabbed and the number of pneumococci isolated by the different methods are not given in the table, so the analysis is a comparison of the vaccine-type pneumococci isolated as a percentage of all pneumococci isolated, stratified by the vaccine received. It is apparent from Table I that there was no protective effect on the carriage of serotype 3, so the analysis is restricted in both studies to serogroups/types other than serotype 3. The numbers of vaccine types (VT) and nonvaccine types (NVT), excluding serotype 3, carried after day 15 by PPV-6 recipients are 11 and 149, respectively, which is a VT carriage rate among all PPV-6 recipient carriers in the carriage study of 6.9%. For the meningococcal vaccine controls, 33 carried VT (excluding serotype 3) and 111 carried NVT for a VT carriage rate of 22.9% of all pneumococci carried by that group after day 15 (difference from PPV-6 vaccines, p<0.001, Fishers exact test). The percentage reduction of VT carriage between these groups was thus 70% (1 minus relative risk of 0.3). Similarly, among the recipients of the saline control, the carriage of VT pneumococci, other than serotype 3, more than 15 days post-vaccination was 26, with 87 NVT isolates detected for a similar carriage rate among all the pneumococci detected of 23% (p=0.002, Fishers exact test compared to PPV-6 recipients). The reduction in VT carriage was again 70%.
Although the number of vaccinees included in the PPV-13 carriage trial was three times less, similar trends were found (Table II) . Although the number of serotype 3 strains in this study was small, they are also excluded in this analysis, to keep the analyses between the studies consistent. Vaccinetype carriage 15 or more days post-vaccination among PPV-13 recipients was six VT strains and 27 NVT, so the percentage of VT pneumococci was 18.2%, compared to 10 VT and 18 NVT among meningococcal controls, percentage VT=35.7% (versus PPV-13, p=0.15, not significant); non-significant reduction in VT carriage is 49%; and among the saline recipient controls 18 VT and 17 NVT, percentage VT=51% (versus PPV-13, p=0.0054); reduction in VT carriage is 65%.
Discussion
If an impact on carriage is the mechanism by which both PCV and PPV reduce non-bacteraemic pneumonia, then the impact of PPV on carriage needs to be studied.
There is, however, a paucity of knowledge on the impact of PPV on carriage. Carriage in the elderly for whom the vaccine has been indicated, is surprisingly low in developed countries, comparing those with access to care 13 to indigenous populations such as the Aborigines.
14 Although PPV has been used to stop outbreaks of invasive pneumococcal disease in institutions, where such an intervention has led to an impact on carriage, that impact could not be separated from other interventions such as antibiotic prophylaxis. 15 In the Papua New Guinea trial of the 14-valent PPV in adults in which there was little evidence of protection against nonbacteraemic pneumococcal pneumonia, but there was an impact against invasive infections and mortality, there was no impact of the vaccine on vaccine-type nasopharyngeal carriage or vaccine types isolated by culture from sputum. 16 In groups in whom the vaccine may have some impact on invasive disease, but not on non-bacteraemic pneumonia, such as children over the age of two years, there has similarly been no impact of PPV on carriage. 17 PPV given to pregnant HIV-infected women did not reduce pneumococcal acquisition in their infants. 18 There is therefore a consensus in the literature that PPV does not impact on carriage.
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The clearest evidence, however, of PPV efficacy against non-bacteraemic pneumonia comes from the randomised trials in young healthy adults conducted by Macleod in 1945, 3 and the Austrian trial for which the carriage data are described above. 4 In the Macleod study there was a significant impact on carriage of the four vaccine types (1, 2, 5, 7) in an analogous calculation to that done in the present study. Carriage was detected in that study post-vaccination among those without pneumonia, of 32 VT pneumococci and 1,180 NVT among the PPV-4 vaccinees (VT carriage percentage 2.6%), compared to 59 VT-carried strains and 1,236 NVT strains (VT carriage percentage 4.5%) among controls (X 2 =8.7; p=0.003). 3 The percentage reduction in carriage of VT strains was thus 43% in that study (1 minus relative risk of 0.57).
Serotype 3 has a particularly viscous capsule that allows it to resist opsonophagocytosis, and the inability of at least one experimental pneumococcal conjugate vaccine to protect against otitis media due to that type 20 is the latest in a long line of failures to induce protection against that type. Nonetheless, the data presented in this paper suggest that there was an impact of PPV-6 against carriage of types other than serotype 3, and for the PPV-13 vaccine; although the carriage study was smaller, there was significant protection compared to the saline control group. In the analysis of the impact of PPV on pneumonia in the Austrian study, the control groups were combined 4 and there is clear evidence of protection for the PPV vaccination then, even including serotype 3, for both studies, compared to the combined control groups (for PPV-6 the VT percentage is 12.4% compared to 25.3% among controls; p=0.0009; VT reduction = 51%; and for PPV-13 the VT percentage is 20.6% compared to 46.2% among the combined controls; p=0.016); VT reduction 55%. These data suggest that there was a significant impact on carriage of vaccine types in both of the PPV studies in which an impact of PPV was demonstrated on non-bacteraemic pneumonia.
There are a number of limitations to this analysis. We do not have access to the original file data of the trial, which was conducted over 30 years ago. We are unsure of the extent to which the laboratory workers who did the serotyping were blinded to the vaccine received by the miners, so there is a possibility of bias. The exact timing of the swabs (beyond two weeks post-immunisation) is not stated, and the extent to which more than one pneumococcal serotype was isolated from the same individual by either of the two techniques used 1  0  1  2  20  0  2  0  2  1  3  2  21  2  0  0  3  1  0  2  22  3  0  2   4  0  1  1  23  1  1  0  5  0  0  0  24  1  4  1  6  0  0  2  25  0  1  5  7  2  1  1  28  2  0  1  8  0  1  0  29  1 is not recorded. Nonetheless, the analysis of carriage of VT versus NVT strains controls against any imbalance in the number of swabs taken from the vaccinees versus the controls. Finally, the vaccine serotypes included in these vaccines are largely the more invasive serotypes, so the vaccine impact against serotypes more likely to be carried rather than to invade may be different, and there is insufficient power in this study to answer that question. All the PPV-6 serotypes would be considered invasive types, but PPV-13 included serogroups/types 6, 9, 14 and 19, which are more likely to be carried, and the number of these carried serogroups/types by PPV-13 vaccinees, more than two weeks post-immunisation, was zero, compared to four among the combined controls.
The data in this study are consistent with the hypothesis that the capsular pneumococcal vaccine impacts on pneumonia may be mediated through protection from carriage. The immunological mechanism by which PCV protects young children from both carriage and pneumonia, and by which PPV (when administered to healthy young adults) likewise protects against both carriage and pneumonia, may be a function of antibody concentration in the blood, but there may be other attributes of the humoral or cellular response to PCV that contribute to their ability to protect from both carriage and pneumonia. As PCV produces a similar quantitative and qualitative antibody response in the blood in elderly adults to PPV, the ability of PCV to impact on carriage in the elderly may be an important predictor of its ability to prevent nonbacteraemic pneumonia in that population.
